A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
Study identifier: NCT01482715
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Rucaparib (previously PF-01367338)
- Locally recurrent or metastatic solid tumor (includes lymphoma, all types of breast cancer) that has progressed on standard treatment (Part 1)
- Locally advanced or metastatic breast cancer that is associated with a gBRCA mutation and that has relapsed following prior treatment, is not HER2+, and is measurable (Part 2).
Type of study:
Phase I/II single-agent. Single group assignment (all participants receive study agent).
Oral tablet administered daily; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day; doses will be escalated in subsequent patient cohorts until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 will receive the RP2D daily for continuous 21-day treatment cycles..
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Julie Pfrommer email@example.com
Page updated 01/10/12
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.